AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11934715
Drug: 0.05 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 ml/kg of 10 mM GSNO
Trial: 10656476
Drug: Self-administered food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered food frequency questionnaire (FFQ) reviewed by a nutritionist
Trial: 10656476
Drug: Self-administered food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered food frequency questionnaire (FFQ) without nutritionist review
Trial: 2328304
Drug: Sublingual dimenhydrinate
RxNorm normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual dimenhydrinate (50 mg)
Trial: 2328304
Drug: Oral dimenhydrinate
RxNorm normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dimenhydrinate (50 mg)
Trial: 2328304
Drug: Intravenous dimenhydrinate
RxNorm normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dimenhydrinate (50 mg)
Trial: 31158718
Drug: MI+CBT (Motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MI+CBT (Motivational Interviewing + Cognitive Behavioral Therapy)
Trial: 31158718
Drug: SC+CBT (Supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC+CBT (Supportive Counselling + Cognitive Behavioral Therapy)
Trial: 29420200
Drug: Anifrolumab 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anifrolumab 1,000 mg
Trial: 26210606
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of alcohol (.6 g/kg)
Trial: 20937602
Drug: Intraperitoneal carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraperitoneal carboplatin in combination with intravenous weekly dose-dense paclitaxel
Trial: 20937602
Drug: Intravenous carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel
Trial: 19448846
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) for 16 weeks
Trial: 17146730
Drug: Indibulin 20
RxNorm normalized name: Indibulin
DrugBank: Indibulin (DB06169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indibulin 20 mg (fed condition)
Trial: 17146730
Drug: Indibulin 20
RxNorm normalized name: Indibulin
DrugBank: Indibulin (DB06169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indibulin 20 mg (fasted condition)
Trial: 17146730
Drug: Indibulin (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indibulin (dose escalation study)
Trial: 17146730
Drug: Indibulin 60
RxNorm normalized name: Indibulin
DrugBank: Indibulin (DB06169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indibulin 60 mg (recommended dose level)
Trial: 11354519
Drug: 17-beta-estradiol (E2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-beta-estradiol (E2) administration (100 microg.d(‐1) x 3.5d -> 200 microg.d(‐1) x 3.5 d -> 300 microg.d(‐1) x 4.0 d)
Trial: 11354519
Drug: 17-beta-estradiol (E2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-beta-estradiol (E2) administration
Trial: 10958250
Drug: Clomipramine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (oral doses of 10-40 mg/day)
Trial: 8291818
Drug: Practice guideline
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practice guideline recommendation with concurrent reminders
Trial: 8291818
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no concurrent reminders)
Trial: 29739677
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g soy protein with 66 mg isoflavone (SPI)
Trial: 29739677
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g soy protein alone (SP)
Trial: 24304002
Drug: rFIXFc (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFIXFc (recombinant factor IX Fc fusion protein) administered weekly (50 IU/kg)
Trial: 24304002
Drug: rFIXFc (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFIXFc (recombinant factor IX Fc fusion protein) administered every 10 days (100 IU/kg)
Trial: 24304002
Drug: rFIXFc (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFIXFc (recombinant factor IX Fc fusion protein) administered as needed for bleeding episodes (20 to 100 IU/kg)
Trial: 24304002
Drug: rFIXFc (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFIXFc (recombinant factor IX Fc fusion protein) for perioperative treatment
Trial: 17980878
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test before IVF cycle
Trial: 17228986
Drug: Uncertainty management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncertainty management intervention delivered during 4 weekly telephone sessions using audiotaped cognitive-behavioral strategies and a self-help manual.
Trial: 10632652
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg b.d.), clarithromycin (500 mg b.d.), amoxycillin (1 g b.d.) for 10 days (OAC)
Trial: 10632652
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (400 mg b.d.), clarithromycin (500 mg b.d.), amoxycillin (1 g b.d.) for 10 days (RAC)
Trial: 3310827
Drug: 0.150 mg
RxNorm normalized name: LEVOTHYROXINE SODIUM 0.150 mg ORAL TABLET [LEVOTHYROXINE SODIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.150 mg levonorgestrel plus 0.030 mg ethinyloestradiol
Trial: 3310827
Drug: 0.150 mg
RxNorm normalized name: LEVOTHYROXINE SODIUM 0.150 mg ORAL TABLET [LEVOTHYROXINE SODIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.150 mg desogestrel plus 0.030 mg ethinyloestradiol
Trial: 27042166
Drug: Thermogenic fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermogenic fat loss supplement (TFLS)
Trial: 20679593
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 75% expectation of receiving active medication
Trial: 20679593
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 25%, 50%, or 100% expectation of receiving active medication
Trial: 20679593
Drug: Prior medication
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior medication response
Trial: 3280999
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy for 12 months (Group A)
Trial: 3280999
Drug: Infant stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant stimulation for 6 months followed by physical therapy for 6 months (Group B)
Trial: 29331971
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (control)
Trial: 31501052
Drug: Inhaled POL6014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled POL6014 (doses 80 to 320 mg in subjects with CF)
Trial: 31501052
Drug: Inhaled POL6014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled POL6014 (doses 20 to 960 mg in healthy volunteers)
Trial: 21958742
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of symptoms
Trial: 21958742
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of β-blocker use
Trial: 20002087
Drug: Low-dose ritonavir
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ritonavir (three oral doses of 100 mg over 24 h)
Trial: 20002087
Drug: ALT-2074 (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALT-2074 (three oral doses of 80 mg over 24 h)
Trial: 17284131
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER (75-225 mg/day)
Trial: 15113944
Drug: Test fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test fat F (5 g/100 g long chain (n‐3) fatty acids)
Trial: 12575603
Drug: Liandai Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liandai Capsule
Trial: 9563534
Drug: Glutamine supplements
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplements (30 g/day)
Trial: 7889887
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg boron/day supplement
Trial: 18394829
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day oral dehydroepiandrosterone (DHEA)
Trial: 18394829
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg transdermal estradiol plus 100 mg/day oral micronized progesterone (HRT)
Trial: 7624736
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g n‐3 PUFAs daily for 6 weeks
Trial: 7624736
Drug: 0.65 g
RxNorm normalized name: Tumil-K 2 MEQ/0.65 GM Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.65 g n‐3 PUFAs daily for 6 weeks
Trial: 2612495
Drug: Lamotrigine (Lamictal)
RxNorm normalized name: LAMOTRIGINE (LAMICTAL) 25MG TAB
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (Lamictal) as add-on therapy
Trial: 944387
Drug: levodopa with
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: levodopa with L-tryptophan
Trial: 29093159
Drug: CNTO6785 15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO6785 15, 50, 100, or 200 mg every 4 weeks + MTX
Trial: 22505632
Drug: Minocycline (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (7 days of intravenous administration)
Trial: 20518927
Drug: MOD cavity
RxNorm normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: MOD cavity preparation (G2)
Trial: 20518927
Drug: MOD +
RxNorm normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: MOD + root canal treatment (G3)
Trial: 19898966
Drug: Intravenous levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous levetiracetam (LEV)
Trial: 10919601
Drug: Machine perfusion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine perfusion (MP) in UW-machine perfusate solution (MPS)
Trial: 3542325
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate (250 mg)
Trial: 3542325
Drug: Metoclopramide hydrochloride
RxNorm normalized name: Metoclopramide Hydrochloride
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide hydrochloride (10 mg)
Trial: 30968534
Drug: Non-Chinese herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Chinese herbal medicine users (controls)
Trial: 30968534
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicines (CHMs) for over 2 years
Trial: 23134887
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient supplementation (vitamin B complex and vitamins C and E) among children whose mothers received ARV therapy
Trial: 18822796
Drug: Hypnotic suggestions
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic suggestions of analgesia during different conditions (pre-hypnosis, neutral hypnosis, suggestions for analgesia, posthypnotic conditions)
Trial: 18822796
Drug: Suggestions for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suggestions for analgesia administered after a mental stress instead of neutral hypnosis
Trial: 18822796
Drug: Hypnotic relaxation
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic relaxation and suggestions of analgesia in healthy Lows receiving nociceptive stimulation
Trial: 16040874
Drug: Asthma clubs
RxNorm normalized name: Hercules Club Whole
DrugBank: Zanthoxylum clava-herculis whole (DB14353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asthma clubs intervention (weekly sessions over 8 weeks)
Trial: 11778093
Drug: 0.5% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% levobupivacaine (group L, n=22)
Trial: 7819687
Drug: Vaginal douche
RxNorm normalized name: Rexall 0.3 % Vaginal Douche
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal douche with chlorhexidine solution (method I)
Trial: 7819687
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate obstetrical gel during vaginal exploration (method II)
Trial: 8098520
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% apraclonidine
Trial: 31608926
Drug: Cotadutide (50-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotadutide (50-300 µg, once-daily subcutaneous)
Trial: 26863738
Drug: Etiotropic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etiotropic therapy with treatment and rehabilitation measures
Trial: 26863738
Drug: Etiotropic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etiotropic therapy alone
Trial: 9395384
Drug: Weekly chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly chloroquine
Trial: 16899213
Drug: Self-help based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-help based on cognitive behaviour therapy with Internet support
Trial: 3046630
Drug: Urapidil (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (30 to 90 mg bid)
Trial: 3046630
Drug: Captopril (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5 to 50 mg bid)
Trial: 28770459
Drug: liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 1.8 mg once daily for 24 weeks
Trial: 23623012
Drug: Phytosterol capsules
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol capsules (2.0 g/d)
Trial: 17085157
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg (single doses)
Trial: 17085157
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg + Tamsulosin 0.4 mg (once daily for up to 14 days)
Trial: 17085157
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg + Tamsulosin 0.4 mg
Trial: 15248191
Drug: Verapamil (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (doses of 120, 180, 360, or 540 mg)
Trial: 11483144
Drug: Adderall (mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adderall (mixed amphetamine salts compound) at an average oral dose of 54 mg (administered in 2 daily doses)
Trial: 7821320
Drug: Flecainide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (2 mg.kg‐1 intravenous bolus in 10 min)
Trial: 7821320
Drug: Dofetilide (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dofetilide (8 micrograms.kg‐1 maximum intravenous bolus in 15 min)
Trial: 31462812
Drug: Fentanyl 3
RxNorm normalized name: FENTANYL 37.5MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 3 μg/kg
Trial: 31462812
Drug: Fentanyl 4
RxNorm normalized name: fentanyl 400 MCG Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 4 μg/kg
Trial: 25521460
Drug: 0.1% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tacrolimus ointment applied twice weekly
Trial: 19339966
Drug: Pregnenolone (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone (fixed escalating doses to 500 mg/day)
Trial: 16940442
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (100 mg daily) + Depomedroxyprogesterone acetate (DMPA, 300 mg/3 months)
Trial: 16940442
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (100 mg daily) + Depomedroxyprogesterone acetate (DMPA, 300 mg/3 months) + Acyline (300 microg/kg every 2 weeks for 12 weeks)
Trial: 22270204
Drug: 5% Acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Acyclovir cream
Trial: 26150057
Drug: Paroxetine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine combined with cognitive‐behavioral therapy
Trial: 26150057
Drug: Paroxetine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine combined with cognitive‐behavioral therapy and virtual reality exposure
Trial: 8126502
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg entacapone
Trial: 24925090
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg opicapone
Trial: 27137718
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg opicapone
Trial: 24925090
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg opicapone
Trial: 23862255
Drug: Plain bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain bupivacaine 10 mg with 25 mcg of fentanyl
Trial: 23862255
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 10 mg with 25 mcg of fentanyl
Trial: 12485511
Drug: Nausea disintegrating
RxNorm normalized name: Pepto Nausea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nausea disintegrating buccal tablet (DBT) 0.1 mg before chemotherapy
Trial: 12485511
Drug: Kytril tablet
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kytril tablet 2 mg after chemotherapy
Trial: 9802273
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (nitrendipine 10-40 mg/day, possibly with enalapril 5-20 mg/day, hydrochlorothiazide 12.5-25 mg/day)
Trial: 7895926
Drug: Amoxicillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (1 g twice daily)
Trial: 7895926
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg twice daily for 14 days, then 20 mg once in the morning for 28 days)
Trial: 2013669
Drug: Salbutamol 4
RxNorm normalized name: Salbutamol 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 4 mg by mouth
Trial: 29119718
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone treatment (15 mg/d)
Trial: 27960026
Drug: NTVC (Topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTVC (Topical vasodilating cream)
Trial: 18338627
Drug: Oral Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Chinese materia medica (b. i. d)
Trial: 18338627
Drug: Oral carboxymethyl
RxNorm normalized name: carboxymethyl fragment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carboxymethyl liquor (control)
Trial: 15847251
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg once daily for four weeks, increased to 80 mg if DBP >= 85 mmHg after four or eight weeks.
Trial: 15847251
Drug: Telmisartan treatment
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan treatment
Trial: 12774056
Drug: G‐CSF stimulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF stimulated stem cell donation
Trial: 10420392
Drug: Microcrystalline chitosan
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline chitosan (MCCh; 3 capsules, each 400 mg b.i.d.)
Trial: 2702229
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose inhaler use
Trial: 27646508
Drug: Control (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (daily feedback without any incentive)
Trial: 20051130
Drug: Pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill placebo (PBO)
Trial: 23786536
Drug: Eplerenone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (100 mg/day) for 1 month